Viscosupplementation Market Companies Analysis

Introduction

The global viscosupplementation market is entering a transformative era, fueled by shifting patient preferences, aging demographics, and relentless medical innovation. According to Renub Research, the industry is projected to grow from US$ 4.66 Billion in 2024 to an impressive US$ 10.16 Billion by 2033, registering a healthy CAGR of 9.02% between 2025 and 2033.

This compelling surge primarily stems from the increasing prevalence of osteoarthritis (OA)—a degenerative condition affecting millions worldwide. As patients seek less invasive, more sustainable pain-management options, viscosupplementation has emerged as a preferred treatment.

The procedure involves injecting hyaluronic acid (HA) directly into the affected joint to restore lubrication, reduce friction, and improve mobility. Often recommended for knee, hip, and hand OA, viscosupplementation provides long-lasting relief—sometimes for up to six months—making it an appealing alternative to corticosteroids or early joint replacement.

What follows is a comprehensive editorial-style analysis of the leading companies shaping this high-growth market, enriched with SWOT insights, recent developments, sustainability efforts, and a granular look at the industry landscape.

Request Free Sample Report

Understanding Viscosupplementation

Viscosupplementation is a minimally invasive procedure designed to restore the natural viscosity of synovial fluid. Exogenous HA injections mimic the body’s natural lubricant, promoting shock absorption, reduced inflammation, and better joint movement.

Key Benefits Include:

Reduced joint pain

Improved mobility and flexibility

Delayed need for surgical intervention

Long-lasting effects vs. steroids

Chondroprotective and disease-modifying potential

As osteoarthritis burden grows globally, viscosupplementation is being increasingly adopted in outpatient orthopedic clinics, hospitals, and specialized pain centers.

Leading Companies in the Viscosupplementation Market

Below is a detailed look at the world’s most influential companies participating in or impacting the viscosupplementation industry.

1. Smith & Nephew PLC

Establishment: 1856 • Headquarters: United Kingdom • Revenue (2023): US$ 5.8B

Website: www.cinfin.com

Smith & Nephew is a medical technology powerhouse with strong footprints in orthopedic reconstruction, sports medicine, and wound care. Its portfolio includes advanced knee and hip replacement systems, robotics-assisted surgery tools, and orthopedic biologics—strengthening its relevance in the viscosupplementation ecosystem.

The company serves physicians, surgeons, purchasing groups, insurers, and hospitals across the Americas, Europe, APAC, and Middle East. Its established brand equity and global reach make it a crucial participant in OA management solutions.

2. F. Hoffmann-La Roche Ltd

Establishment: 1896 • Headquarters: Switzerland

Website: www.roche.com

Roche is a global biotechnology leader with strong presence in diagnostics, oncology, autoimmune diseases, and advanced therapeutics. While not a viscosupplementation-focused manufacturer, its innovations in biologics and personalized medicine indirectly shape the HA-based therapeutics landscape.

Its diagnostics and research tools enable better OA detection and monitoring, while its pioneering medical research continues to influence treatment protocols worldwide.

3. Sanofi

Establishment: 1973 • Headquarters: France

Revenue (2023): US$ 47.9B

Website: www.sanofi.com

Sanofi stands as one of the world’s largest pharmaceutical companies, offering a rich portfolio of vaccines, biologics, women’s health products, and specialty care therapies. Its extensive R&D ecosystem and advanced biologics manufacturing enable it to integrate seamlessly into OA treatment segments, including HA research and joint-health-related therapy pipelines.

The company operates across 100+ countries, supported by stringent regulatory compliance and strong commercialization capabilities.

4. Chugai Pharmaceutical Co.

Establishment: 1925 • Headquarters: Japan

Revenue (2023): US$ 8.1B

Website: www.chugai-pharm.co.jp

Chugai, a Roche subsidiary, is a prominent biopharmaceutical entity known for its innovations in biotechnology and regenerative medicine. Its strong focus on musculoskeletal diseases, immunology, and oncology positions it as a key contributor to emerging treatment methodologies in osteoarthritis.

Its presence across Europe, North America, and Asia ensures a diversified geographical footprint.

5. Lifecore Biomedical

Establishment: 1965 • Headquarters: United States

Website: www.lifecore.com

Lifecore Biomedical is a globally recognized CDMO specializing in HA-based solutions. Renowned for producing some of the world’s highest-quality pharmaceutical-grade sodium hyaluronate, the company plays a critical role in supporting viscosupplementation developers.

Its end-to-end support—from formulation to aseptic fill-finish—makes it a preferred partner for pharmaceutical and biotech firms working on HA-based injectables.

SWOT Analysis of Key Market Players

LG Life Sciences Ltd

Strengths — Comprehensive R&D and Manufacturing Powerhouse

LG Life Sciences’ integrated R&D-manufacturing ecosystem offers unmatched scalability and efficiency. With strong IP, global regulatory compliance, and robust biologics capabilities, it stands out as a high-impact force in advanced pharmaceutical development.

Opportunities — Growing Demand in Emerging Markets

The rise of precision medicine and biologics across SEA, Latin America, and Africa creates lucrative opportunities. LG can expand through partnerships, localized manufacturing, and targeted therapy launches.

DePuy Synthes (Johnson & Johnson MedTech)

Strengths — One of the World’s Largest Orthopedic Portfolios

DePuy Synthes offers advanced joint reconstruction solutions, trauma implants, robotic surgery systems, enabling technologies, and sports medicine tools. Innovations like the VELYS™ Robotic-Assisted Solution and ATTUNE™ Knee System enhance outcomes and deepen customer loyalty.

Opportunities — Expanding in High-Growth APAC & LATAM Markets

Aging populations and better healthcare access are fueling orthopedic surgeries in emerging economies. With J&J’s distribution strength, DePuy Synthes is positioned to accelerate adoption of its knee OA solutions globally.

Fidia Farmaceutici S.p.A

Strengths — Global Leader in HA Technology

Fidia maintains an unmatched HA patent portfolio with ~1,250 patents dedicated to HA production. Its leadership in biomaterials anchors its global dominance in viscosupplementation, ophthalmology, and wound care.

Opportunities — Growing Demand for HA in APAC & Africa

By introducing cost-optimized HA therapies and forming regional partnerships, Fidia can unlock new demand in rapidly industrializing nations facing rising OA burden.

Recent Developments in the Viscosupplementation Market

March 2025: Anika Therapeutics sharpened its strategy on HA-based pain relief by divesting Parcus Medical to Medacta Group.

October 2024: Bioventus sold its Advanced Rehabilitation division to Accelmed Partners for US$ 45 million plus earn-outs.

January 2024: Zimmer Biomet launched VISCO3, a three-injection high-molecular-weight HA therapy for knee OA across several markets. Clinical results show 52% pain reduction at 12 weeks, lasting up to six months.

These developments highlight a trend toward portfolio optimization, specialization, and globally diversified product launches.

Viscosupplementation Market & Forecast Overview

Historical Trends

Previously dominated by single-injection therapies, the market has now diversified into multi-injection, single-dose, and cross-linked HA variations for customized patient outcomes.

Forecast Analysis

With a projected US$ 10.16 Billion valuation by 2033, the market is set for strong growth due to:

Rising OA prevalence

Non-surgical treatment preferences

Improved HA formulations

Growth of outpatient orthopedic clinics

Market Share Analysis

Key leaders—including Fidia, Anika Therapeutics, Zimmer Biomet, and LG Life Sciences—maintain dominance due to innovation, distribution strength, and extensive clinical data.

Company-Wide Strategic Assessment Framework

Below categories apply across all major companies listed:

1. Overview

Company origin, mission, and evolution

Milestones and innovation timelines

2. Business Model & Operations

Core segments (pharmaceuticals, devices, biologics, CDMO services)

Revenue channels

Market expansion strategies

3. Workforce

Employee base

R&D team strength

Global office and production site distribution

4. Leadership

Executive board

Division heads

Decision-making structure

5. Recent Developments

Mergers & acquisitions

Regional expansion

Investment in biologics & HA technologies

6. Sustainability Initiatives

Renewable energy adoption

Waste management

Water conservation

Eco-efficient packaging strategies

7. Product Analysis

Product profiles

Quality standards

Regulatory approvals

Safety and efficacy benchmarking

Pipeline innovations

8. Strategic SWOT

Competitive strengths

Operational weaknesses

Market opportunities

Threats from regulatory shifts & competition

9. Revenue Analysis

Annual financial performance

Regional contribution

Segment-wise growth

Companies Covered in Full Analysis

Anika Therapeutics Inc.

Zimmer Biomet

Smith & Nephew PLC

F. Hoffmann-La Roche Ltd

Sanofi

Chugai Pharmaceutical Co.

Lifecore Biomedical

LG Life Sciences Ltd

DePuy Synthes

Fidia Farmaceutici S.p.A

Seikagaku Corp.

Ferring Pharmaceuticals B.V.

Wellchem Pharmaceuticals Pte Ltd

OrthogenRx, Inc.

Bioventus LLC

Final Thoughts

The viscosupplementation market is poised for robust and sustained growth, driven by aging populations, rising osteoarthritis rates, and patient preference for less-invasive pain-relief treatments. As innovations in HA cross-linking, biologics, and long-acting injectables continue, the industry will likely witness a wave of product diversification and competitive pricing.

Leading companies—from Fidia with its unmatched HA expertise to Zimmer Biomet with its breakthrough VISCO3 launch—are shaping the future of joint health with targeted therapies, stronger R&D investments, and global expansion strategies.

For investors, medical professionals, and healthcare strategists, viscosupplementation represents a high-value, innovation-rich segment worth watching closely through 2033 and beyond.